Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | Weblinks | Poem/Story | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Agoraphobia

Description

Literally agoraphobia is a "fear of open spaces".
A clinical definition is "a fear of open spaces, especially those in which getaway may be difficult, which leads to avoidance of the situation". Being in the provoking situation usually leads to an anxiety attack.
There are three basic elements:

  • Phobia
  • Avoidance of situations that might provoke the anxiety
  • Severe anxiety

It can involve a number of phobias which may overlap e.g. presence of crowds or travelling alone.
Once patients are in the provoking situation they develop sudden and severe anxiety - the anxiety is what they try to avoid.
Some patients can manage to continue their daily lives (with difficulty), whilst others are severely affected and may even become incapacitated.

Epidemiology
  • Very common in primary care setting
  • Tends to affect females more than males
  • Commonest age of occurrence is 25- 35
  • Prevalence rates of panic disorder have been quoted around the 1% level - suggesting it to be a chronic and common disorder which is probably underdiagnosed so that the prevalence is much higher.1
  • Agoraphobia affects up to one third of patients with panic disorders.1
Diagnosis

Panic attacks and agoraphobia are underdiagnosed and therefore a high index of suspicion is required.
Diagnosis requires the following:2

  1. Avoidance of situations that provoke the anxiety (prominent feature). In the case of agoraphobia this involves not going out of the house and avoiding open spaces.
  2. Symptoms (psychological and physical) arise mainly from anxiety and the anxiety is not secondary to other underlying psychiatric problems e.g. depression.
  3. Anxiety manifests primarily in two or more of the following: crowds, public places, travelling alone or away from home.
Differential Diagnosis

This includes:3

Management

Non-Drug

  • Cognitive behavioural therapy - this involves exposure to the provoking situation and staying until anxiety passes. 4 This can be done through imagination or in vivo. However, this method can produce severe anxiety and can be very distressing for the patients and therefore needs to be performed in controlled situations. Never the less, cognitive behavioural therapy is superior to supportive psychotherapy alone. Some studies even suggest that CBT may be superior to TAD's.5
  • Education - understand the problem
  • Lifestyle changes - avoid alcohol and illicit drugs and stimulants6
  • Self help groups - focus on relaxation and breathing exercises

Drugs

Benzodiazepines

Give short term relief and are not generally recommended as addictive and do not provide a long term solution. Patients who are already on long term benzodiazepines can be enrolled into CBT sessions and then an attempt made to gradually taper the dose of the benzodiazepine.7

Antidepressants

Tricyclic antidepressants can reduce panic severity and frequency of episodes. A meta-analysis found that antidepressants are just as effective as selective serotonin reuptake inhibitors (SSRI's).8 However, TAD's can be associated with side effects. Monoamine oxidase inhibitors have also been used and appear to produce good results but their side effect profile and associated dietary restrictions makes them unattractive.

SSRI's

These are first line. Paroxetine or fluoxetine have been used with good effects. Escitalopram is a highly selective serotonin reuptake inhibitor and appears as effective as other SSRI's in agoraphobia.9 Venlafaxine a serotonin-norepinephrine reuptake inhibitor is also as effective as SSRI's.10 The Committee on Safety of Medicines (CSM) advises that venlafaxine should be started and maintained under the supervision of a specialist due to concern regarding toxicity when taken in overdose.11

Prognosis

Some patients may improve, however relapses are common. 1 in 3 patients have underlying depression and 1 in 5 will attempt suicide.


Document References
  1. Guidelines for the management of anxiety disorders.; McIntosh A, Cohen A, Turnbull N, Esmonde L, Dennis P, Eatock J, Feetam C, Hague J, Hughes I, Kelly J, Kosky N, Lear G, Owens L, Ratcliffe J, Salkovskis P (2004) Clinical Guidelines and Evidence Review for Panic Disorder and Generalised Anxiety Disorder Sheffield: University of Sheffield/London: National Collaborating Centre for Primary Care.
  2. BehaveNet - Criteria for Agoraphobia
  3. Andrews G, Slade T; Agoraphobia without a history of panic disorder may be part of the panic disorder syndrome.; J Nerv Ment Dis. 2002 Sep;190(9):624-30. [abstract]
  4. Roy-Byrne PP, Craske MG, Stein MB, et al; A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder.; Arch Gen Psychiatry. 2005 Mar;62(3):290-8. [abstract]
  5. Ham P, Waters DB, Oliver MN; Treatment of panic disorder.; Am Fam Physician. 2005 Feb 15;71(4):733-9. [abstract]
  6. Austin D, Blashki G, Barton D, et al; Managing panic disorder in general practice.; Aust Fam Physician. 2005 Jul;34(7):563-71. [abstract]
  7. Spiegel DA, Bruce TJ; Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials.; Am J Psychiatry. 1997 Jun;154(6):773-81. [abstract]
  8. Bakker A, van Balkom AJ, Spinhoven P; SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis.; Acta Psychiatr Scand. 2002 Sep;106(3):163-7. [abstract]
  9. Dhillon S, Scott LJ, Plosker GL; Escitalopram: a review of its use in the management of anxiety disorders.; CNS Drugs. 2006;20(9):763-90. [abstract]
  10. Pollack MH, Lepola U, Koponen H, et al; A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.; Depress Anxiety. 2006 Aug 7;. [abstract]
  11. British National Formulary British Medical Association and Royal Pharmaceutical Society of Great Britain. London.
Acknowledgements EMIS is grateful to Dr Gurvinder Rull for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 1565
Document Version: 20
DocRef: bgp24565
Last Updated: 7 Nov 2006
Review Date: 6 Nov 2008




















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page